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Abstract Transferrin (Tf) is a glycoprotein respon-
sible for iron transport in the human body. Physiolog-
ically in reaction with Concanavalin A, Tf occurs in
four distinct variantsTf1, Tf2, Tf3 (apo-Tf) and Tf4. It
was reported recently that Tf is changing, particularly
during acute phase response, taking place among
others in end-stage renal disease. In this study, we
wanted to ﬁnd the answer to three main questions:
ﬁrstly, how Tf is changing in patients treated with
maintenancehaemodialysis (mHD),secondly,whether
there are any Tf changes in the course of mHD
treatment, and thirdly, what factors can affect Tf
microheterogeneity in these patients. Studies were
performed on 80 haemodialysed patients and 21
healthy volunteers. The Tf concentration was deter-
mined by the rocket immunoelectrophoresis, and its
microheterogeneity was assessed by the ConA crossed
immunoafﬁnity electrophoresis. During the annual
observation of the distribution of the Tf variants, we
have found both changes of the percentage contents of
all Tf variants in the whole Tf concentration and a
signiﬁcant decrease in Tf2, Tf3 and Tf4 serum
concentrations. Moreover, we found that decrease in
therenalfunction,durationofmHD,andinﬂammation
may contribute to these above-mentioned changes,
which are probably the factors that should be taken
into account when explaining the mechanisms of
persistence of anaemia in haemodialysed patients.
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Introduction
Anaemia is very common in patients with chronic
kidney disease (CKD). Factors likely contributing to
anaemia in CKD include blood loss, shortened red
cell life span, vitamin deﬁciencies, the ‘‘uremic
milieu’’ (a term that attempts to explain the multiple
organ dysfunction of CKD), erythropoietin (EPO)
deﬁciency, iron deﬁciency, and inﬂammation. Much
is known about the participation of the above-
mentioned factors in anaemia, but this knowledge is
still incomplete. One of the not-yet-fully-explained
disturbances is that of iron balance in CKD. The
process of human body iron homoeostasis is a very
complex issue, and its main part was described in
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Not fully understood and explained phenomenon
of persistent anaemia and especially unexplained iron
balance disturbances in patients with CKD has
become the reason for the design of this study.
It should be noticed that, in CKD, the ability to
provide enough iron for erythropoiesis is disrupted at
several points in the body iron cycle. One of these
points is iron transport. The protein responsible for
this transport is transferrin (Tf). For reasons not yet
fully explained, Tf levels in CKD are one-half to one-
third of normal levels, diminishing the capacity of the
iron-transporting system. This situation is then aggra-
vated by the well-known inability to release stored
iron from macrophages, scavenging iron from senes-
cent red blood cells and from hepatocytes in CKD [4].
There are two main reasons for which this study
focused on the changes in Tf in CKD. First, we know
little about these changes in CKD. Second, in CKD
several factors exist, like inﬂammatory process and
malnutrition, which may contribute to the Tf changes.
In this part of the work, to understand the
qualitative changes of Tf, its chemical structure and
variability will be presented. Tf (79.57 kDa) consists
of three substructural domains: a single polypeptide
chain, arranged in two lobes, representing the N-
terminal and C-terminal halves of the molecule [5],
two independent, structurally similar but functionally
distinct iron-binding sites and usually two N-linked
complex glycan chains. It should be noticed that the
oligosaccharide chains are usually composed of a
common pentasaccharide core and various quantity of
sialic acid residues, galactose and/or fucose mole-
cules and N-acetylglucosamine, creating the anten-
nary chains. They differ also in the degree of
branching (antennarity), where to the most basic
biantennary structure additional antenna may be
bound, producing tri-, tetra- or even more antennary
glycans [6, 7].
A schematic representation of the transferrin
molecule is shown in Fig. 1.
The heterogeneity of N-glycan chains, varying iron
load (depending on iron supply) and modiﬁcation of
the polypeptide chain (Tf variants) create a distinct Tf
microheterogeneity [8]. If the Tf molecules contain
oligosaccharides of different structures, this phenom-
enon is known as a ‘‘major microheterogeneity’’ [9];
in turn, the difference in the quantity and quality of
the oligosaccharides residues is qualiﬁed as the
‘‘marginal microheterogeneity’’ [10].
In many physiological and pathological condi-
tions, like stress, pregnancy [11, 12], alcoholism [6],
liver failure in alcoholics [13] the changes in the
number of Tf variants, changes in their proportions,
and the presence of completely new variants have
been revealed. All of these studies emphasized the
important inﬂuence of the inﬂammatory process and
oxidative stress on these changes.
Despite numerous studies on the variability of Tf,
little is known about the importance of each of its
variants. The results obtained from few previously
conducted studies are inconclusive. For humans, an
increase in afﬁnity of Tf receptors for higher branched
glycans, was reported by Rudolph [14], but could not
be conﬁrmed by other authors, like Le ´ger et al. [11]
and van Dijk et al. [15]. It should be emphasized that
the binding of transferrin to its receptor on the cell
surface is crucial in iron metabolism, because it
allows the transfer of iron directly into the cell.
Although we have little information about the
participation of individual variations in the transport
of iron, changes in their proportions seem to be
important in maintaining the iron disturbances CKD.
Only few studies have been conducted on this topic
so far. In our preliminary studies [16, 17, 18, 19, 20],
we tried to ﬁnd the answer to one main question
(a)
(b)
Fig. 1 Schematic representation of the transferrin molecule.
(a) Tetra-sialo-Tf while in (b) penta-sialo-Tf are shown
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123of whether the microheterogeneity proﬁle of Tf is
changing in CKD, particularly in haemodialysed
patients, in whom these changes could be particularly
relevant. Based on the results of these studies, it can
be concluded that Tf is changing both quantitatively
and qualitatively in haemodialysed patients. It was
revealed that the sera concentrations of three of the
four variants, i.e. Tf1, Tf2 and Tf4, increased, while
the Tf3 variant decreased, when compared to healthy
volunteers as controls. Moreover, the proportion of
those variants in the whole Tf differed signiﬁcantly
between studied patients and controls. The limitation
of these studies was the small sample size. Therefore,
in the present study we have focused on a thorough
analysis of the Tf microheterogeneity phenomenon in
a larger group of haemodialysed patients. On the
other hand, we wanted to ﬁnd the answer to two other
questions: ﬁrst, whether there are any changes in the
Tf in a course of 1 year of maintenance haemodial-
ysis treatment (mHD), and secondly, what factors can
affect Tf microheterogeneity in these patients. To the
best of our knowledge, results from such analyses
have not been published so far.
Materials and methods
Patients and healthy controls subjects
This study was carried out on a group of 101 subjects,
i.e. 80 patients (mHD group) from the Department of
Nephrology, Transplantology and Internal Medicine,
at Poznan ´ University of Medical Sciences, enrolled
to the haemodialysis treatment, according to The
National Kidney Foundation Kidney Disease Out-
comes Quality Initiative (NKF KDOQI
TM) guidelines
[21] on the basis of their estimated glomerular
ﬁltration rate (eGFR)—calculated by the 4-variable
MDRD Study equation, i.e. serum creatinine, age,
race, and gender [22], and 21 healthy volunteers as
controls (HV group). Patients were examined twice,
i.e. at the beginning (mHD1) and after 1 year of the
study (mHD2). For every examined person the
demographic data, including age and gender were
recorded. Additionally, from all haemodialysed
patients, clinical data, like eGFR, kidney disease
diagnosis, comorbid conditions, current treatments,
i.e. the doses of rHuEPO and iron, the duration of
end-stage renal disease (ESRD) before enrolling to
HD (months) and the duration of HD treatment
(months) were collected.
Haemodialysis sessions were performed three
times a week, for 4 h each, with polysulphone
capillary dialysers, to achieve dialysis adequacy Kt/
V[1.2.
After HD sessions, depending on the individual
patient’s clinical status and EPO responsiveness,
patients received intravenous erythropoietin alpha
[Eprex
]. Furthermore, undiluted iron sucrose–ferric
hydroxide saccharin [Venofer
]) treatment in addi-
tion to EPO was administered according to NKF
KDOQI
TM guidelines. Intravenous iron was pre-
scribed in slow injection (B20 mg/min) given
directly into the dialysis line. The goal of adminis-
tering iron sucrose was to maintain TSAT between 30
and 45%, serum ferritin between 200 and 800 ng/ml,
Hb between 11 and 12.5 g/dl, and Hct between 33
and 36%.
We included in the study only those mHD patients
who met the following criteria: a stable clinical state,
no recent thrombosis or acute infection, absence of
inﬂammation, i.e. normal serum concentration of
C-reactive protein, interleukin-1 and interleukin-6
and TNF-alpha, no comorbid iron metabolism dis-
turbances at present, i.e. high serum ferritin and low
serum iron level, without uncontrolled hypertension,
no oral contraception in women of child-bearing age,
stable and no more than twice the normal alanine
aminotransferase and aspartate aminotransferase
levels (upper range 45 U/l). None of the patients
investigated had received blood transfusions during
the previous 1.5 months.
The control group (HV) consisted of 21 age- and
sex-matched healthy volunteers without any labora-
tory and clinical symptoms of anemia or inﬂamma-
tion. All of them had normal renal function, estimated
by urinalysis, creatinine serum concentration and
eGFR.
The characteristics of the studied groups are
shown in Table 1.
Design of the study
Approval was obtained from the local ethics com-
mittee before the start of the study, and all partici-
pants gave a written informed consent.
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patient and control was deﬁned when ﬁrst blood
sample was drawn. Blood samples were drawn from
mHD patients before a midweek dialysis session
(before heparin administration), at the same time as
their usual monitoring blood tests were performed,
and after the dialysis session, from the arterial line
of the haemodialysis system, immediately before
the disconnection of the extracorporeal circulation
(only for urea concentration, necessary for standar-
dised Kt/V, a marker of adequacy of dialysis
determination). Standard Kt/V was measured accord-
ing to Gotch and Sargent formula [23]. Blood was
drawn without stasis.
All patients and healthy volunteers underwent a
thorough physical examination. The following an-
thropometrical data were determined: weight, height,
body mass index (BMI) and waist-to-hip ratio (WHR)
(see in Table 3). In all subjects, the selected serum
parameters (detailed further), including selected hae-
matological parameters, proteins and cytokines, lipid
proﬁle, and liver function tests at baseline and after
one year follow-up were recorded. In haemodialysed
patients, serum ferritin and serum iron were assessed
1 week following administration of intravenous iron.
Blood samples were taken within the same period in
fastingpatientsandinfastingcontrolsubjects.Thesera
were immediately separated by centrifugation after
clottingandfrozenat-80Cuntilanalysis.Allsamples
were run in duplicate. They were stored and processed
in an identical fashion. All tests were performed
according to the manufacturer’s instructions.
The methodology used for the laboratory tests was
as follows:
Analysed parameters used for characteristics
of the studied groups
Selected haematological parameters
The red blood cell count (RBC) [10
12/l], haematocrit
(HCT) [%], haemoglobin (HGB) [g/dl], mean cor-
puscular haemoglobin (MCH) [pg] and mean corpus-
cular volume (MCV) [ﬂ] were estimated by a
conductometry method, using haematological ana-
lyser (Sysmex K-4500, ICN).
The values of the total iron-binding capacity
(TIBC) [lmol/l], unsaturated iron-binding capacity
(UIBC) [lmol/l] and serum iron concentration (Fe)
[lmol/l] were evaluated by a colorimetric method
Table 1 General characteristics of the studied groups
Studied groups mHD HV as controls
mHD1 mHD2
Number of studied subjects (men/women) 50/30 13/8
Age (years) 55.6 ± 14 56.6 ± 14 54.8 ± 16
eGFR (kg/min/1.73 m
2) 5.5 ± 6.9 4.31 ± 2.9 115.6 ± 31.9
Diagnosis (number of subjects) Glomerulonephritis (40) —
Diabetic nephropathy (31)
Hypertensive nephrosclerosis (9)
Number of subjects with cardiovascular disease 64 —
Number of subjects supplemented with rHuEPO 70 74 —
Weekly doses of rHuEPO [IU] (mean dose among patients getting rHuEPO) 4039 ± 2592 4260 ± 2847 —
Number of subjects supplemented with iron 65 69 —
Weekly doses of iron [mg] (mean dose among patients getting iron) 41.05 ± 63.758 106 ± 84.297 —
Time of ESRD before enrolling to HD (months) 19 ± 2—
Time of HD treatment (months) 46 ± 65 8 ± 6—
Subjects were divided into patients treated with maintenance haemodialysis (mHD1—at the beginning of the study, mHD2—after
1 year of the study) and healthy volunteers (HV) as controls
Results were given as mean ± SD
eGFR estimated glomerular ﬁltration rate, rHuEPO recombinant human erythropoietin, ESRD end-stage renal disease, HD
haemodialysis
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123with ferrozin, using biochemical analyser (Cobas
Integra, Roche).
The saturation of transferrin (TSAT) [%] was
calculated as a ratio of the serum iron concentration
to the value of the TIBC.
Serum ferritin (sFn) [ng/mL] was estimated by a
chemiluminescence method with the mice monoclo-
nal antibodies speciﬁc to the human ferritin, using
immunochemical analyser (Elecsys 2010, Roche).
The serum concentrations of the selected haema-
tological parameters used for characteristics of the
studied groups are presented in Table 2.
Selected proteins and cytokines
For the quantitative determination of serum C-reac-
tive protein (CRP) [mg/l]—N high sensitivity CRP
reagent (hs CRP)—, an in vitro diagnostic assay
consisting of a suspension of polystyrene particles
coated with the mouse monoclonal antibodies to CRP
and nephelometer (DADE Behring Analyzer II) were
used.
The sera interleukin 6 (IL-6), interleukin 1 (IL-1)
and tumour necrosis factor alpha (TNF-a) [pg/ml]
concentrations were evaluated by an enzyme-linked
immunosorbent assay (ELISA) method using (R&D
Systems) Quantikine HS human IL-6 kit, IL-1 kit and
TNF kit, respectively.
Selected liver metabolism parameters
The serum bilirubin concentration (mg/dl) was
assessed by colorimetric method by using Cobas
Integra Analyser (Roche).
The activities of the aminotransferases, the alanine
aminotransferase (ALT) [IU/l] and the aspartate
aminotransferase (AST) [IU/l], were measured by
kinetic method using Cobas Integra Analyser (Roche).
The concentration of albumin was determined by
immunonephelometric, using a set of N-Antiserum to
Table 2 Selected haematological parameters used for characteristics of the studied groups
Parameter mHD P value
mHD1 vs. mHD2
HV as controls
mHD1 mHD2
RBC (10
12/l) 3.25 ± 0.47*** 3.11 ± 0.42*** 0.03 4.6 ± 0.8
HCT (%) 33.3 ± 318*** 32.31 ± 3.9*** 0.64 44.3 ± 7.2
HGB (g/dl) 10.62 ± 1.54*** 10.5 ± 1.21*** 0.76 14.9 ± 2.0
MCH (pg) 32.86 ± 4.79 34.16 ± 3.7 0.15 34.2 ± 3.7
MCV (fL) 98.68 ± 5.86*** 98.91 ± 5.72*** 0.81 104.6 ± 11.1
TIBC (lmol/l) 37.66 ± 5.27*** 42.4.8 ± 8.47*** 0.0001 59.6 ± 5.3
UIBC (lmol/l) 21.92 ± 8.04*** 17.942 ± 8.2*** 0.0021 36.4 ± 3.1
Fe (lmol/l) 15.73 ± 6.68*** 15.06 ± 7.86*** 0.63 22.7 ± 9.1
sFn (ng/ml) 1749.55 ± 179.98*** 1804.72 ± 1086.53*** 0.88 188.2 ± 10.6
TSAT (%) 42.6 ± 18.95*** 37.84.8 ± 24.7*** 0.21 38.4 ± 6.5
Subjects were divided into patients treated with maintenance haemodialysis (mHD1—at the beginning of the study, mHD2—after
1 year of the study) and healthy volunteers (HV) as controls
The differences between mHD1 and mHD2 were estimated by paired t test. To compare mHD1 and mHD2 with HV as controls,
unpaired the Student’s t test for normally distributed variables and the Mann–Whitney rank sum test for the variables with non-
normal distribution were used
Data were given are means ± SD
mHD1 patients treated with maintenance haemodialysis at the beginning of the study, mHD2 patients treated with maintenance
haemodialysis after 1 year of the study, RBC red blood cells, HCT haematocrit, HGB haemoglobin, MCH mean haemoglobin
concentration, MCV mean corpuscular volume, TIBC total iron-binding capacity, UIBC unsaturated iron-binding capacity, Fe serum
iron, sFn serum ferritin, TSAT transferrin saturation
Signiﬁcant differences when P\0.05
*** P\0.001 versus HV
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nephelometer Dade Behring Analyzer II.
Selected lipids metabolism parameters
Total cholesterol and triglycerides were determined
by colorimetric method with glycerol phosphate
oxidase and 4-aminoantipyrine (GPO/PAP), using a
biochemical analyzer Cobas Integra 400, Roche.
Results were expressed in units of mmol/l.
The serum concentrations of the analysed proteins
and cytokines, liver metabolism parameters and lipid
parameters used for characteristics of the studied
groups are shown in Table 3.
Laboratory determinations
In every patient and control, apart from parameters
that became put-upon to the characteristics of the
examined groups, transferrin serum concentrations
and transferrin microheterogeneity were examined.
Transferrin concentration
To measure transferrin serum concentration (mg/l),
the rocket immunoelectrophoresis according to
Laurell [24] was used. The 1% agarose (Prona) in
Tris–HCl buffer, pH 8.6, was boiled and then cooled
down to 56C. Agarose contained 40 ll rabbit anti-
human transferrin (Daktopatts). Then, it was cast on
the plates. Electrophoresis was performed with 3 ll
sample serum (10-fold dilutions) and standard human
serum (Daktopatts) (10- and 5-fold dilutions) at
1.5 V/cm for 8 h. Afterwards the plates were pressed,
dried and stained with Coomassie Brilliant Blue
R-250. Total serum concentrations of Tf were
counted by using a planimetrical method. The areas
of precipitations were proportional to the quantity of
the antigen, i.e. Tf.
Table 3 Anthropometrical parameters, liver metabolism parameters and inﬂammatory markers in mHD group (mHD1—at the
beginning of the study, mHD2—after 1 year of the study) and in healthy volunteers (HV) as controls
Parameter mHD P value
mHD1 vs. mHD2
HV as controls
mHD1 mHD2
WHR 0.95 ± 0.22 0.94 ± 0.12 0.86 0.97 ± 0.05
BMI (kg/m
2) 25.16 ± 4.69 24.56 ± 4.75 0.07 25.6 ± 4.3
Cholesterol (mg/dl) 178.9 ± 47.4 173 ± 36.6 0.49 170.8 ± 24.3
Triglycerides (mg/dl) 179 ± 22.6** 175.7 ± 23.2** 0.54 92.3 ± 26.5
Albumin (g/l) 38.091 ± 5.34** 36.73 ± 4.12** 0.19 44.7 ± 1.71
Bilirubin (mg/dl) 0.6 ± 0.22 0.6 ± 0.13 0.91 0.6 ± 0.1
ALT (IU/l) 15.34 ± 7.8 15.38 ± 6.2 0.83 15.57 ± 7.4
AST (IU/l) 16.39 ± 5.7 16.44 ± 7.42 0.87 16.57 ± 6.31
hsCRP (mg/l) 7.42 ± 3.56** 13.29 ± 12.03*** 0.00018 2.3 ± 0.6
IL-1 (pg/ml) 3.98 ± 0.67*** 8.41 ± 1.88*** 0.00000 0.6 ± 0.01
IL-6 (pg/ml) 36.82 ± 39.84*** 48.01 ± 109.72*** 0.5 4.3 ± 0.7
TNF-alpha (pg/ml) 28.74 ± 70.7*** 25.57 ± 21.10*** 0.79 1.2 ± 0.1
The differences between mHD1 and mHD2 were estimated by paired t test. To compare mHD1 and mHD2 with HV as controls,
unpaired the Student’s t test for normally distributed variables and the Mann–Whitney rank sum test for the variables with non-
normal distribution were used
Data were given are means ± SD
WHR waist-to-hip ratio, BMI body mass index calculated as follows: BMI = weight (kg)/[height (m)]
2, ALT alanine
aminotransferase, AST aspartate aminotransferase, hsCRP high sensitivity C-reactive protein, IL-1 interleukin 1, IL-6 interleukin
6, TNF-alpha tumour necrosis factor-alpha
Signiﬁcant differences when P\0.05
** P\0.01; *** P\0.001 versus HV
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Transferrin microheterogeneity was assessed by the
crossed immunoafﬁnity electrophoresis according to
Bog-Hansen [25]. The 1% agarose (Prona, Spain) in
Tris–HCl buffer, pH 8.6, was prepared as mentioned
earlier. The ﬁrst dimension gel (17.5 ml) contained
1.5 mg/ml lectin, i.e. Concanavalin A (ConA) as the
diantennary-speciﬁc afﬁnocomponent. Afterwards
agarose was cast on the glass plates. Electrophoresis
was performed with 10 ll sample serum (10-fold
dilutions in 0.9% NaCl) at 10 V/cm and with
Bromophenol Blue (BPB) mixed with albumin
(marker of migration) for 2 h. Next, a single slab,
corresponding to migration of single sample serum,
was submitted to the crossed immunoafﬁnity electro-
phoresis with anti-Tf. The second dimension gel
(5.5 ml) contained 26 ll rabbit anti-human transferrin
(Daktopatts, Danmark) and a displacer, i.e. 1.5 mg/ml
methyl a-D-glucopyranoside (this sugar ousts the
glycoprotein from her bond with the lectin and makes
possible the migration of the protein in II direction).
Electrophoresis was run at 1.5 V/cm for 18 h on the
second dimension plates, two slabs per plate. Then the
plates were pressed, dried and stained with Coomassie
Brilliant Blue R-250 and the relative occurrences of
lectin-retarded and lectin-non-retarded glycoforms
were calculated from the areas under the curves.
Statistical analyses
Statistical analysis was performed using Statistica 8.0
package. Data were expressed as mean values ± SD
(standard deviation) from 101 subjects. For testing the
normality of variable distributions, the Shapiro–Wilk
test was used. Non-parametrical tests were performed
for the analysis of the non-normally distributed
variables. For the comparison of variables obtained
from patients at the beginning (mHD1) and after
1 year of the study (mHD2), paired t test was used. To
compare mHD1 and mHD2 with HV as controls,
unpaired the Student’s t test for normally distributed
variables and the Mann–Whitney rank sum test for the
variables with non-normal distribution were used. To
calculate the correlations between demographic data,
selected variables, used form characteristics of the
studied groups and the Tf variants, Spearman’s rank
correlation coefﬁcient was used. The signiﬁcance
level was assumed to be equal to 0.05.
Results
Analysis of the rocket immunoelectrophoresis
patterns according to Laurell
The areas of precipitations proportional to the
quantity of serum Tf showed the differences between
mHD patients (the exemplary sera samples nos.
1–12) and healthy volunteers (the exemplary sera
sample nos. I–II) (see Fig. 2).
After planimetrical analysis of the results, a
considerable decrease in total serum Tf concentration
in mHD group if compared to HV was found. The
results summarised in Table 4 indicate a 2.5-fold
decrease in the total amount of Tf between mHD
patients (in both mHD1 and mHD2 groups) and HV
group. However, no statistically signiﬁcant changes
in Tf were observed during 1 year of maintenance
haemodialysis treatment, i.e. between mHD1 and
mHD2 (see Table 4).
Analysis of the ConA crossed immunoafﬁnity
electrophoresis patterns
The crossed immunoafﬁnity electrophoresis with
ConA revealed four distinct Tf variants, i.e. Tf1,
Tf2, Tf3 and Tf4 in the studied sera (see Figs. 3, 4).
Fig. 2 The Tf patterns analysed by the rocket immunoelec-
trophoresis according to Laurell. (I–II) Standard solutions
(controls); (1–6) sera samples from selected patients from
mHD1group, (6–12) sera samples from selected patients from
mHD2 group
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niﬁcant differences between mHD patients and HV
group, particularly in the Tf3 serum concentration.
At the beginning of the study (mHD1), sera concen-
trations of Tf1, Tf2 and Tf3 were signiﬁcantly lower,
in contrast to Tf4, if compared to HV group.
After 12 months of study, similar changes, except
for changes of Tf1 were observed. It should be
mentioned here that the changes in Tf2 and Tf3 has
intensiﬁed. In addition, there was statistically signif-
icant decrease in the serum concentration of Tf4,
which was not observed previously.
The per cent distribution of Tf variants in the whole
serum Tf differed between studied groups, see on
Fig. 5.InmHDgroups,thepercentagecontentsofTf1,
Tf2 and Tf4 variants in the total serum Tf were higher
than in HV, contrary to Tf3 variant, whose percentage
content decreased if compared to HV. Furthermore,
interesting seems to be the decrease in the percentage
content of Tf3variant inthe total serum Tf observed in
haemodialysed patients during the study.
It should be noted that after 1 year of the study, we
did not observe any signiﬁcant changes in the studied
parameters in healthy subjects. For the clarity of the
analyses, these results have not been presented.
Analysis of the factors affecting the variability
of Tf
Table 5 demonstrates only these correlations that were
statisticallysigniﬁcantatthebeginningandafter1 year
Table 4 The serum concentrations of total Tf were estimated by the rocket immunoelectrophoresis according to Laurell. After the
obtainment of the precipitates, the results were counted on the basis on the planimetrical analysis of the surfaces of these precipitates
Parameter (mg/l) mHD P
mHD1 vs. mHD2
HV as controls
mHD1 mHD2
Tf 1408.27 ± 410.98*** 1386.486 ± 426.726*** 0.82 3532.123 ± 761.31
Tf1 132.035 ± 63.17* 152.34 ± 62.97 0.19 150.12 ± 51.1
Tf2 227.412 ± 76.56*** 324.513 ± 124.59 0.0002 332.11 ± 121.1
Tf3 942.957 ± 321.25*** 802.21 ± 401.31*** 0.021 2882.91 ± 721.3
Tf4 150.865 ± 60.70 97.21 ± 44.46*** 0.00024 150.871 ± 91.23
Subjects were divided into patients treated with maintenance haemodialysis (mHD1—at the beginning of the study, mHD2—after
1 year of the study) and in healthy volunteers (HV) as controls
The differences between mHD1 and mHD2 were estimated by paired t test. To compare mHD1 and mHD2 with HV as controls,
unpaired Student’s t test for normally distributed variables and the Mann–Whitney rank sum test for the variables with non-normal
distribution were used
Tf—serum transferrin, Tf1–Tf4—Tf variants
Data were given are means ± SD
Signiﬁcant differences when P\0.05
* P\0.05; *** P\0.001 versus HV
Fig. 3 Tf microheterogeneity patterns of serum of selected
healthy volunteer analysed by the crossed afﬁnoimmunoelec-
trophoresis according to Bog-Hansen in the presence of
Concanavalin A in the ﬁrst-dimension gel (the horizontal
pointer) and rabbit anti-human transferrin in the second-
dimension gel (the perpendicular pointer)
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mHD1andmHD2groups,werefoundforthefollowing
associations:Tf3andthedurationofHDtreatment,Tf3
and hsCRP and Tf3 and IL-6. Moreover, Tf3 variant
showed signiﬁcant positive correlations with HGB,
RBC, Fe and eGFR. No statistically signiﬁcant corre-
lationsinbothstudiedgroupofhaemodialysedpatients
wereobservedbetweenremainingTfvariantsandthese
above-mentioned parameters.
Furthermore, we did not ﬁnd any other correlations
between Tf variants and age, sex, the existence of car-
diovascular disease, hypertension, diabetes mellitus,
WHR, BMI, selected liver metabolism parameters,
TNF-alpha and rHuEPO and iron doses.
Discussion
Chronic kidney disease shares several features of the
inﬂammatory state. One link between elevated levels
of pro-inﬂammatory cytokines and poor treatment
outcomes in CKD patients may be the presence of
anaemia. Evidence suggest several mechanisms, like
suppression of bone marrow erythropoiesis [26],
Fig. 4 Tf microheterogeneity patterns of sera of selected
patients treated with maintenance haemodialysis analysed by
the crossed afﬁnoimmunoelectrophoresis according to Bog-
Hansen in the presence of Concanavalin A in the ﬁrst-
dimension gel (the horizontal pointer) and rabbit anti-human
transferrin in the second-dimension gel (the perpendicular
pointer)
Fig. 5 Per cent distribution of Tf variants in the whole
transferrin serum concentration in studied groups. Subjects
were divided into patients treated with maintenance haemod-
ialysis (mHD patients) and healthy volunteers (HV). In the
mHD group, there are two subgroups: mHD1 (patients at the
beginning of the study) and mHD2 (the same group of patients
after 12 months of the study)
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123suppression of EPO production [27], increased intes-
tinal bleeding [28] and modulation of iron metabo-
lism [29, 30] by which inﬂammatory cytokines may
affect the development of anaemia.
Our paper dealt with the issue related to iron
deﬁciency in dialysis patients. There are three known
main mechanisms that have been proposed to explain
the high frequency of iron deﬁciency in these
patients, in addition to the increased demand for iron
and consequent storage in RBCs when erythropoiesis
is stimulated with rHuEPO. These include abnormal
iron absorption, external blood loss and functional
iron deﬁciency [31]. The last mentioned disturbance,
observed also in patients from our study, is present
when the usual tests for iron deﬁciency in dialysis
patients do not indicate absolute iron deﬁciency
(ferritin of more than 100 ng/ml; TAST of more than
20%), but patients respond to additional iron admin-
istration with a rise in haematocrit at a stable rHuEPO
dose or maintain a stable haematocrit with a lower
rHuEPO dose [32]. Patients with functional iron
deﬁciency therefore have apparently insufﬁcient
available iron to keep up with the demands of the
stimulated erythropoiesis that occur when rHuEPO
is administered. In some patients, the inability to
mobilise iron rapidly depends on the presence of
reticulo-endothelial blockade, which may be the
effect of the increased levels of cytokines [32]. In
general, circulating cytokines may impair iron
metabolism via several different mechanisms [33].
This persistent chronic inﬂammatory state may
contribute to the changes of variability in Tf levels
and hyporesponsiveness to proper treatment often
seen in CKD patients. Modiﬁcation in glycosylation
of acute phase proteins (APPs), Tf being one of them
(negative APPs), evoked by the changes in cytokine
concentration, can be studied using a crossed immu-
noafﬁnity electrophoresis with lectins, e.g. Conca-
navalin A. This lectin strongly binds covalently to bi-
antennary sugar chains and does not bind tri-, tetra- or
more branched glycans, nor structures with bisecting
N-acetylglucosamine [34]. Therefore, protein mole-
cules can be divided into ConA-reactive variants
(with predominantly bi-antennary glycans) and ConA
non-reactive variants, i.e. more branched. This men-
tioned electrophoresis allows the complete resolution
of human Tf into variants. The number of four Tf
variants found in this study agrees with this reported
by Sobiesiak [35] and by Grzymisławski et al. [36].
On the other hand, according to Le ´ger et al. [11],
human serotransferrin was resolved only into three
carbohydrate molecular variants, i.e. TfI (two tri-
antennary glycans), TfII (one tri-antennary glycans
and one bi-antennary glycans) and TfIII (two bi-an-
tennary glycans), corresponding to Tf1, Tf2 and Tf3,
respectively. The main difference in comparison with
our results was the lack of Tf4.
Following is the description of the different
variants, supplemented by information about their
reaction with ConA during electrophoresis, together
with a discussion of the obtained results.
The ﬁrst Tf variant (Tf1) is not retarded in reaction
with ConA, it means that it bears glycans that ConA
cannot bind (tri or more antennary) or sugars
incomplete or completely absent. It is known that
this variant raises both in chronic and in acute stages
of the diseases [35]. Our results did not conﬁrm these
ﬁndings. At the beginning of the study, we observed a
slightly statistically signiﬁcant decrease in the serum
Table 5 Statistically signiﬁcant correlations found in haemo-
dialysed patients
Tf3
mHD1 mHD2
Duration of HD treatment r =- 0.41
P = 0.04
r =- 0.43
P = 0.033
eGFR r = 0.88
P = 0.0001
r = 0.55
P = 0.004
RBC r = 0.57
P = 0.003
r = 0.55
P = 0.004
HGB r = 0.4
P = 0.004
r = 0.88
P = 0.0001
Fe r = 0.55
P = 0.004
r = 0.58
P = 0.002
hsCRP r =- 0.46
P = 0.019
r =- 0.047
P = 0.021
IL-6 r =- 0.176
P = 0.041
r =- 0.186
P = 0.029
mHD1—patients at the beginning of study and mHD2—
patients after 1 year of the study
To calculate the correlations—Spearman’s rank correlation
coefﬁcient was used
Tf3 variant of transferrin, HD haemodialysis, eGFR estimated
glomerular ﬁltration rate, RBC red blood cells, HGB haemo-
globin,Feserumiron,hsCRPhighsensitivityC-reactiveprotein,
IL-6 interleukin 6
Signiﬁcant correlation when P\0.05
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123concentration of this variant, but at the end its
concentration did not differ if compared to controls.
Moreover, the differences between mHD1 and mHD2
were not signiﬁcant, despite the fact that during the
annual observation we noticed an increase in the
inﬂammatory process in mHD patients. However,
during the annual observation, the percentage content
of this variant in the concentration of the total serum
Tf increased in comparison with the results obtained
at the start of the study and when we compared these
results with controls. Further studies are required to
know how important this variant is in iron transport.
The second variant (Tf2) reacts slightly with
ConA, thus this variant should carry bi-antennary
sugar chains. This could be a glycoform with two
chains: one bi- and the other tri-antennary, the so-
called ‘pentasialo Tf’ [35]. Tf2 may consist also of
two isomeric three-antennary chains Noismith and
Field [34]. During this study, we have observed that
its serum concentration increased similarly to the
percentage contents in the total Tf serum concentra-
tion. However, its serum concentration after 1 year of
the study did not differ signiﬁcantly in comparison
with controls. As with the previous Tf, determining
the signiﬁcance of this variant in the transport of iron
requires further research.
The Tf3 is the most dominant one. It is strongly
retarded in electrophoresis with ConA; thus, it carries
molecules with two bi-antennary sugar chains, the so-
called tetrasialo Tf. Probably this variant is apotrans-
ferrin (apoTf) free for iron transport in the human
organism [35, 37]. Normally, all of non-haem iron in
the circulation is bound to holotransferrin (holoTf).
Only about 30% of Tf binding sites are occupied, so
that most of this protein is free of iron and is able to
bind one or two Fe
3? ions in transferrins’ N- and/or
T-terminal ends (Nt (Fe
3?) holoTf or holoTf (Fe
3?)
Ct or holoTf (Fe
3?)2). ApoTf competes with bacteria
for the free iron ions to limit an infection and after the
binding with the iron it is transformed into holoTf, so
its concentration decreases. Indirect conﬁrmation that
Tf3 is probably apo-Tf, we found in the results of our
research. Namely, in mHD patients we observed a
reduction in UIBC, a parameter reﬂecting the level of
Tf, which has not been used for the transport of iron,
and this reduction correlated with the lowering Tf3. It
should highlight, however, that a statistically signif-
icant relationship between mentioned parameters was
detected only in patients from mHD2 group, so we
did not put it into result set. Our results, both at the
beginning and after 12 months of the observation,
showed the lower concentration of serum Tf3 and the
lower percentage content of Tf3 in the total Tf serum
concentration, if compared to HV. It should be noted
that after 1 year of the study these changes intensi-
ﬁed. This is particularly important because this
variant is likely the crucial one in the transport of
iron, which was indirectly conﬁrmed in the observed
correlations, i.e. positive correlations between Tf3
and Fe, HGB, RBC, respectively. Furthermore, our
results revealed that impaired renal function and the
duration of the mHD treatment may have an inﬂuence
on the serum concentration of this variant (positive
correlations between these parameters). However, it
seems that the main factor that inﬂuences Tf3 is the
inﬂammatory process. Indirect proofs of this impact
are the inverse correlations between the concentration
of this variant and both hsCRP and IL-6.
Thelastvariant,i.e.Tf4variant,istheslowestonein
a crossed immunoafﬁnity electrophoresis with ConA.
Its mobility may be inﬂuenced by other heterogeneity
factors like saturation with iron, the quantity of sialic
acid or any changes in the structure of the protein [35].
During 1 yearofourstudy,itwasrevealedthatitisthe
serum concentration that decreased, similarly to its
percentagecontent inthe totalTfserumconcentration.
On the other hand, the almost double increase in
percentage content of this variant in mHD group in
comparison with HV group was found. This phenom-
enonisprobablyconnectedwithintensiveprocessesof
the reconstruction of the Tf oligosaccharides chains
observed during chronic inﬂammatory process, and
therefore the increase in the quantity of Tf with
defectible carbohydrates was observed in our study.
As was mentioned earlier, Tf,produced by the liver,
belongstoAPPsandmodiﬁcationsofitsglycosylation,
evokedmainlyby the changesofcirculatingcytokines,
maybeimportantindicatorofacutephaseresponse.To
make sure that the changes observed in our study are
not due to factors whose impact is commonly known,
i.e.liverdysfunctionandnutritionalstatus—wetriedto
rule out their inﬂuence on the results. On the other
hand,weassessedonlyWHR,BMIandserumalbumin
levels, so we cannot with certainty exclude the impact
of nutritional status on the observed changes, although
the parameters examined, i.e. WHR, albumins, BMI,
didnotindicate that nutritionalstatus could explain the
obtained the results.
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concentration of Tf, the higher serum concentrations
of ferritin, C-reactive protein and selected cytokines,
i.e. IL-1, IL-6 and TNF-alpha found during this study
conﬁrmed the existence of the chronic inﬂammatory
process in studied patients. Many chronic diseases,
including end-stage renal disease, are associated with
spuriously high serum ferritin levels notwithstanding
low tissue iron levels, what we have also observed in
our study. Historically, serum ferritin was thought to
increase when intracellular ferritin levels were high,
so that high serum levels of this protein were
indicative of intracellular ferritin concentration or
intracellular stores. Two lines of evidence challenge
this thesis. First, intracellular ferritin appears to be a
completely different protein species than circulating
in serum. Second, it is also known to increase non-
speciﬁcally as an acute phase reactant [32].
Totestwhethertheinﬂammatoryprocessitselfmay
induce changes observed during this examination, we
conducted an additional analysis. For this purpose, we
examined twice, at the beginning and after 1 year of
the treatment, 10 haemodialysed patients without
clinical and laboratory features of chronic inﬂamma-
tion. In this small group of patients, we found similar
changes of the variability of Tf variants to those
observed in the main groups of mHD patients. The
only difference was the consistency of these changes,
i.e. no statistically signiﬁcant differences were
revealed during the annual follow-up. Moreover, the
per cent content of Tf variants in the whole serum Tf
was similar to changes observed in mHD1 group.
These results were not included into this work because
of too small number of patients enrolled to the study
group. We mention them to indicate that inﬂammation
is an important factor that inﬂuences Tf variants, but it
seems that it is not the only one.
Summarising, the inﬂammatory process in CKD
has an inﬂuence on Tf and, in particular, on its
variants. In our study, we observed that during 1 year
of the haemodialysis treatment the serum concentra-
tion of the total Tf was constant, but lower if
compared to controls, whereas the percentage of the
individual Tf variants changed. It is worth to mention
that alterations in the glycosylation proﬁle of serum
proteins may occur faster than in its general concen-
tration, which could suggest peripheral binding of
selected variants or further processing in peripheral
blood or tissues. Synthesis and glycosylation are
regulated distinctly [37]. Assessments of APPs may
even be more reliable than the exemplary IL-6 serum
concentration, as this cytokine is produced locally
and quickly catabolised [35].
Pathogenesis of the anaemia associated with CKD
and mHD is multi-factorial, and new factors are still
investigated. The Tf heterogeneity changes may be
one such additional new factors. Future research is
needed to clarify this issue.
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